Prolonged continuous infusion of low-dose rIL-2. by Janssen, R. A. et al.
Br. J. Cancer (1994), 69, 976 © Macmillan Press Ltd., 1994
LETTER TO THE EDITOR
Prolonged continuous infusion of low-dose rIL-2
Sir - We read with interest the paper of Vlasveld et al.
(1993), in which they report on the immunological aspects of
constant infusion of low-dose recombinant interleukin 2 (IL-
2) in melanoma and renal cell carcinoma patients, including
the possible activation of T cells. When measured at weeks 0,
3 and later, they found that the number of T cells decreased,
the CD4/CD8 ratios did not change, and there was no
increased expression of CD25 and CD27, and no increased
proliferation upon stimulation of peripheral blood lym-
phocytes with CD3 monoclonal antibody (MAb) with or
without CD28 MAb. Therefore the authors concluded that
prolonged low-dose IL-2 therapy does not induce T-cell
activation.
We would like to comment that these observations might
be influenced by the time points of analysis. In a longitudinal
study during low-dose subcutaneous IL-2 therapy we demon-
strated that IL-2 therapy does induce T-cell activation, as
assessed by the increased expression of HLA-DR, during the
first week of therapy, followed by a decrease in the number
of T cells expressing the activated phenotype (Janssen et al.,
1993). Other investigators have reported T-cell activation
during low-dose continuous intravenous infusion (Yoshino et
al., 1991).
It has been demonstrated that T cells sampled during IL-2
therapy become unresponsive to in vitro stimulation with
CD3 MAb (Weil-Hillman et al., 1991; Janssen et al., 1993).
This might imply that IL-2 therapy induces T-cell anergy,
causing the decrease in activated peripheral T cells during
prolonged therapy. Another explanation could be the redist-
ribution of activated and highly responding T cells to the
tissues, leaving the low-responding T cells in the circulation.
Taken together, these findings might explain why Vlasveld et
al. did not find T-cell activation after 3 weeks of therapy.
There is mounting evidence that T cells play an important
role in IL-2 therapy-induced anti-tumour activity (Parmiani,
1990; loannides & Whiteside, 1993; Maas et al., 1993). It is
therefore necessary to gain more insight in the ways in which
T cells become activated during IL-2 therapy.
We conclude that low-dose IL-2 therapy can induce T-cell
activation, although only temporarily in the first week of
treatment. We suggest that researchers who are interested in
T-cell activation during IL-2 therapy pay particular attention
to the events induced during the early course of IL-2 therapy.
Yours etc.
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